These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32402065)

  • 1. The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management.
    Sabouret P; Galati G; Angoulvant D; Germanova O; Castelletti S; Pathak A; Metra M; Margonato A
    Eur Heart J Cardiovasc Pharmacother; 2020 Nov; 6(6):394-404. PubMed ID: 32402065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis.
    Pinto LC; Rados DV; Remonti LR; Viana LV; Pulz GT; Carpena MP; Borges RP; Marobin R; Beretta MV; Pedrollo EF; Londero TM; Machry R; Janeczko L; Moehlecke M; Falcetta MR; Bauer AC; Silveiro SP; Gerchman F; Rodrigues TC; Kramer CK; Bertoluci MC; Leitão CB
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32797182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging glucose-lowering therapies: a guide for cardiologists.
    Gulsin GS; Graham-Brown MPM; Davies MJ; McCann GP
    Heart; 2020 Jan; 106(1):18-23. PubMed ID: 31551292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials : Perspective on GLP-1 RA and SGLT-2i therapies.
    Ludwig L; Darmon P; Guerci B
    Cardiovasc Diabetol; 2020 May; 19(1):65. PubMed ID: 32404155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
    Natali A; Nesti L; Tricò D; Ferrannini E
    Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
    Schernthaner G; Shehadeh N; Ametov AS; Bazarova AV; Ebrahimi F; Fasching P; Janež A; Kempler P; Konrāde I; Lalić NM; Mankovsky B; Martinka E; Rahelić D; Serafinceanu C; Škrha J; Tankova T; Visockienė Ž
    Cardiovasc Diabetol; 2020 Oct; 19(1):185. PubMed ID: 33097060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antihyperglycemic Therapies With Expansions of US Food and Drug Administration Indications to Reduce Cardiovascular Events: Prescribing Patterns Within an Academic Medical Center.
    Hamid A; Vaduganathan M; Oshunbade AA; Ayyalasomayajula KK; Kalogeropoulos AP; Lien LF; Shafi T; Hall ME; Butler J
    J Cardiovasc Pharmacol; 2020 Sep; 76(3):313-320. PubMed ID: 32569016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New anti-diabetic agents: major advances with unanswered questions.
    Sabouret P; Bocchino PP; Biondi-Zoccai G
    Rev Cardiovasc Med; 2020 Dec; 21(4):489-492. PubMed ID: 33387991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT-2 Inhibitors and GLP-1 Agonists: First-Line Therapy for Diabetes With Established Cardiovascular Disease.
    Sajja AP; Dey AK; Guha A; Elnabawi Y; Joshi AA; Kalra A
    J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):422-427. PubMed ID: 31064213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off.
    Giugliano D; Scappaticcio L; Longo M; Bellastella G; Esposito K
    Cardiovasc Diabetol; 2021 Oct; 20(1):205. PubMed ID: 34641876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms.
    Savarese G; Butler J; Lund LH; Bhatt DL; Anker SD
    Cardiovasc Res; 2022 Jul; 118(10):2231-2252. PubMed ID: 34390570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
    Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 Jun; 17(1):85. PubMed ID: 29895290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report from the 5th cardiovascular outcome trial (CVOT) summit.
    Schnell O; Standl E; Cos X; Heerspink HJ; Itzhak B; Lalic N; Nauck M; Ceriello A
    Cardiovasc Diabetol; 2020 Apr; 19(1):47. PubMed ID: 32303223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current landscape for diabetes treatment: Preventing diabetes-associated CV risk.
    Dardano A; Bianchi C; Garofolo M; Del Prato S
    Atherosclerosis; 2024 Jul; 394():117560. PubMed ID: 38688748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification tools for heart failure in the diabetes clinic.
    Cannistraci R; Mazzetti S; Mortara A; Perseghin G; Ciardullo S
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1070-1079. PubMed ID: 32475628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.